Tolera Therapeutics, Inc.

John J Puisis

Daniel R Getts

James J Herrmann

Frank J Fokta

The present invention provides compositions, methods, and assays for treating an inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using anti-&#x3b1;&#x3b2; TCR antibodies and antibody fragments. Anti-&#x3b1;&#x3b2; TCR antibodies are antibodies which bind to a &#x3b1;&#x3b2; TCR. Anti-&#x3b1;&#x3b2; TCR antibodies produced by the hybridoma TOL101 MCB are also provided. Methods for treatment of an inflammatory disease, an autoimmune disease and for tissue transplant rejection using therapeutic dosing regimen of anti-&#x3b1;&#x3b2; TCR antibodies and antibody fragments and for upregulating the numbers of Treg T-cells are also provided

Antibody and methods for selective inhibition of T-cell responses

The present invention provides compositions, methods, and assays for treating an inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using anti-&#x3b1;&#x3b2; TCR antibodies and antibody fragments. Anti-&#x3b1;&#x3b2; TCR antibodies are antibodies which bind to a &#x3b1;&#x3b2; TCR. Anti-&#x3b1;&#x3b2; TCR antibodies produced by the hybridoma TOL101 MCB are also provided. Methods for treatment of an inflammatory disease, an autoimmune disease and for tissue transplant rejection using therapeutic dosing regimen of anti-&#x3b1;&#x3b2; TCR antibodies and antibody fragments and for upregulating the numbers of Treg T-cells are also provided. The present invention also provides methods of treating inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using a therapeutic amount of ex vivo expanded regulatory T-cells.

The present invention provides compositions, methods, and assays for treating an inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using anti-&#x3b1;&#x3b2; TCR antibodies and antibody fragments. Anti-&#x3b1;&#x3b2; TCR antibodies are antibodies which bind to a &#x3b1;&#x3b2; TCR. Anti-&#x3b1;&#x3b2; TCR antibodies produced by the hybridoma TOL101 MCB are also provided. Methods for treatment of an inflammatory disease, an autoimmune disease and for tissue transplant rejection using therapeutic dosing regimen of anti-&#x3b1;&#x3b2; TCR antibodies and antibody fragments and for upregulating the numbers of Treg T-cells are also provided.

Growing community of inventors

Glenview, IL, United States of America

John J Puisis